First Tracks Biotherapeutics, Inc.
No enriched coverage for $TRAX in the last 7 days.
No SEC Form 4 filings for $TRAX in the last 30 days.
See all $TRAX insider activity →First Tracks Biotherapeutics (TRAX) closed a private placement of 6.1M common shares and signed a Registration Rights Agreement with investors. The company must file a resale registration statement with the SEC by Oct 19, 2026, to facilitate investor liquidity. The agreement is effective immediately and can be terminated at will.
First Tracks Biotherapeutics, Inc. (TRAX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 19, 2026 (the “Closing Date”), First Tracks Biotherapeutics, Inc. (the “Company”) closed its previously announced private placement (the “Private Placement”) of an aggregate 6,106,870 shares (the “Shares”) of the Co
First Tracks Biotherapeutics, Inc. (TRAX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. First Tracks Biotherapeutics Announces $200 Million Private Placement SAN DIEGO, CA — Oct. 15, 2026 — First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune a
Recent TRAX coverage spans corporate actions, market movers and financial news.
The registration rights may increase short‑term share supply, creating modest downward pressure.
Dilution from the new shares may weigh on the stock, while the registration rights could support future resale activity.
The financing is likely dilutive but provides near-term funding for ANB033 clinical development, shifting risk from liquidity to execution.
The sizable capital raise will likely dilute existing shareholders, creating short-term price pressure despite the cash infusion.
Analyst endorsement may lift sentiment and attract buying interest.
AlphAI scores every news story that mentions TRAX with an AI model for sentiment and relevance, and aggregates insider trades from First Tracks Biotherapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
First Tracks Biotherapeutics (TRAX) closed a private placement of 6.1M common shares and signed a Registration Rights Agreement with investors. The company must file a resale registration statement with the SEC by Oct 19, 2026, to facilitate investor liquidity. The agreement is effective immediately and can be terminated at will.
2 min readFirst Tracks Biotherapeutics, Inc. (TRAX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 19, 2026 (the “Closing Date”), First Tracks Biotherapeutics, Inc. (the “Company”) closed its previously announced private placement (the “Private Placement”) of an aggregate 6,106,870 shares (the “Shares”) of the Co
1 min readFirst Tracks Biotherapeutics, Inc. (TRAX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. First Tracks Biotherapeutics Announces $200 Million Private Placement SAN DIEGO, CA — Oct. 15, 2026 — First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune a
4 min readFirst Tracks Biotherapeutics (TRAX) announced a $200M private placement, selling 6.11M shares at $32.75 each to institutional investors.
1 min readGuggenheim named First Tracks Biotherapeutics (TRAX) its top biotech pick after positive argenx data. The firm sees TRAX's upcoming 2026 celiac disease data as promising, with potential stock valuation between $2.5B and $3B. TRAX's management is confident in their study design and power.
1 min readCanaccord raised its price target for First Tracks Biotherapeutics (TRAX) to $60 from $50, maintaining a Buy rating. The move follows positive Phase Ib trial data for ANB033 in celiac disease, showing statistically significant improvements in histological measures and patient-reported symptoms. The stock is currently at $34.05, up 79% year-to-date. Multiple analysts have recently initiated or raised price targets for TRAX, reflecting optimism about its pipeline.
2 min readFirst Tracks Biotherapeutics, Inc. stock's average price target increased to $72.08 from $71.25 by 12 analysts, with a range of $57 to $100. This implies a 126% upside from the Oct. 9 closing price. All 12 analysts maintain a 'Buy' rating.
1 min readThe Dow Jones gained 200 points, while NASDAQ and S&P 500 showed mixed results. Chipotle shares fell 4% after Starbucks denied acquisition rumors. First Tracks Biotherapeutics, J-Star Holding, and Euro Tech Holdings rose, while Service Properties Trust, China SXT Pharmaceuticals, and TTM Technologies declined. Commodities saw oil rise and gold fall. European and Asian markets also showed mixed results.
7 min readFirst Tracks Biotherapeutics (TRAX) stock rose 22.9% pre-market after positive Phase 1b trial results for ANB033 in celiac disease. The drug showed significant improvements over placebo and was well tolerated. The company plans late-stage development in 2027. Analysts have raised price targets, with Wells Fargo increasing its target to $62. The broader market was flat.
1 min readFirst Tracks Biotherapeutics (TRAX) shares hit an all-time high after HC Wainwright raised its price target to $44, citing positive clinical results from competitor Forte Biosciences (FBRX). TRAX was up 13% and FBRX over 20% on Friday. Both companies target the CD122 pathway for autoimmune therapies.
1 min read
